Evidence for an acute phase response in human intestinal epithelial cells.
During the host response to inflammation/tissue injury there are many changes in intermediary metabolism including a dramatic change in the concentrations of many "acute phase" plasma proteins. Although many of these acute phase proteins are predominantly derived from the liver and the response can be elicited from liver cells incubated in tissue culture with cytokines such as interleukin-6 (IL-6), interleukin-1 (IL-1), tumor necrosis factor-alpha, interferon-gamma, leukemia inhibitory factor, interleukin-11 (IL-11), and oncostatin M, there is now evidence that the response can also be elicited in extrahepatic tissues and cell types. In this study, we show that many of the acute phase plasma proteins are expressed in human intestinal epithelial cell lines Caco2 and T84 and that their expression is induced or regulated by cytokines IL-6, IL-1, interferon, and tumor necrosis factor in a manner characteristic of the acute phase response. In fact, effects of IL-1 and IL-6 which are additive, synergistic, and antagonistic in liver cell lines are also observed in these intestinal epithelial cell lines. Responses to IL-6 and IL-1 are seen at all stages of differentiation of Caco2 cells from crypt-like enterocytes to villus-like enterocytes. Caco2 cells express binding sites for IL-6 at both poles, for IL-1 at the basolateral pole and, to a lesser extent, at the apical pole. T84 cells have IL-1 and IL-6 receptor binding sites only at the basolateral pole. IL-6 and IL-1 also regulate the expression of enterocyte-specific integral membrane proteins as exemplified by down-regulation of sucrase-isomaltase gene expression in response to IL-6. These data raise the possibility that enterocytes are involved in a local response to injury/inflammation at the epithelial surface and establish a model system for examining coordination of the acute phase response in a bipolar cell.
Molmenti
E P
EP
Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110.
Ziambaras
T
T
Perlmutter
D H
DH
D000209:Acute-Phase Proteins / Q000096:biosynthesis*; D000230:Adenocarcinoma; D002454:Cell Differentiation; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D003110:Colonic Neoplasms; D011415:Complement Factor B / Q000096:biosynthesis; D016207:Cytokines / Q000494:pharmacology*; D004815:Epidermal Growth Factor / Q000494:pharmacology; D004848:Epithelium / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D007375:Interleukin-1 / Q000378:metabolism / Q000494:pharmacology; D015850:Interleukin-6 / Q000378:metabolism / Q000494:pharmacology; D007413:Intestinal Mucosa / Q000378:metabolism*; D007700:Kinetics; D008715:Methionine / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D013462:Sulfur Radioisotopes; D014168:Transferrin / Q000096:biosynthesis; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D000514:alpha 1-Antichymotrypsin / Q000096:biosynthesis; D000515:alpha 1-Antitrypsin / Q000096:biosynthesis
D000209:Acute-Phase Proteins; D016207:Cytokines; D007375:Interleukin-1; D015850:Interleukin-6; D011994:Recombinant Proteins; D013462:Sulfur Radioisotopes; D014168:Transferrin; D014409:Tumor Necrosis Factor-alpha; D000514:alpha 1-Antichymotrypsin; D000515:alpha 1-Antitrypsin; D004815:Epidermal Growth Factor; D007371:Interferon-gamma; D008715:Methionine; D011415:Complement Factor B